

## Product datasheet for **SR306681**

### **DLEC1 Human siRNA Oligo Duplex (Locus ID 9940)**

#### **Product data:**

<b>Product Type:</b>	siRNA Oligo Duplexes
<b>Purity:</b>	HPLC purified
<b>Quality Control:</b>	Tested by ESI-MS
<b>Sequences:</b>	Available with shipment
<b>Stability:</b>	One year from date of shipment when stored at -20°C.
<b># of transfections:</b>	Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM).
<b>Note:</b>	Single siRNA duplex (10nmol) can be ordered.
<b>RefSeq:</b>	<a href="#">NM_005106</a> , <a href="#">NM_007335</a> , <a href="#">NM_007336</a> , <a href="#">NM_007337</a> , <a href="#">NM_007338</a> , <a href="#">NM_001321153</a>
<b>UniProt ID:</b>	<a href="#">Q9Y238</a>
<b>Synonyms:</b>	deleted in lung and esophageal cancer 1; deleted in lung cancer 1; DLC1; F56; F56, DLC1
<b>Components:</b>	DLEC1 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 9940) Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol Included - SR30005, RNase free siRNA Duplex Resuspension Buffer - 2 ml
<b>Summary:</b>	The cytogenetic location of this gene is 3p21.3, and it is located in a region that is commonly deleted in a variety of malignancies. Down-regulation of this gene has been observed in several human cancers including lung, esophageal, renal tumors, and head and neck squamous cell carcinoma. In some cases, reduced expression of this gene in tumor cells is a result of aberrant promoter methylation. Several alternatively spliced transcripts have been observed that contain disrupted coding regions and likely encode nonfunctional proteins. [provided by RefSeq, Mar 2016]



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.

For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).